Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 9/10

vs
industry
vs
history
Cash-to-Debt No Debt
SGEN's Cash-to-Debt is ranked higher than
99% of the 943 Companies
in the Global Biotechnology industry.

( Industry Median: 54.02 vs. SGEN: No Debt )
Ranked among companies with meaningful Cash-to-Debt only.
SGEN' s Cash-to-Debt Range Over the Past 10 Years
Min: No Debt  Med: No Debt Max: No Debt
Current: No Debt
Equity-to-Asset 0.77
SGEN's Equity-to-Asset is ranked higher than
61% of the 709 Companies
in the Global Biotechnology industry.

( Industry Median: 0.67 vs. SGEN: 0.77 )
Ranked among companies with meaningful Equity-to-Asset only.
SGEN' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.36  Med: 0.62 Max: 0.96
Current: 0.77
0.36
0.96
Interest Coverage No Debt
SGEN's Interest Coverage is ranked higher than
99% of the 453 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. SGEN: No Debt )
Ranked among companies with meaningful Interest Coverage only.
SGEN' s Interest Coverage Range Over the Past 10 Years
Min: No Debt  Med: No Debt Max: No Debt
Current: No Debt
Piotroski F-Score: 3
Altman Z-Score: 30.13
Beneish M-Score: -2.54
WACC vs ROIC
17.35%
-261.01%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating Margin % -43.50
SGEN's Operating Margin % is ranked higher than
60% of the 737 Companies
in the Global Biotechnology industry.

( Industry Median: -92.31 vs. SGEN: -43.50 )
Ranked among companies with meaningful Operating Margin % only.
SGEN' s Operating Margin % Range Over the Past 10 Years
Min: -260.49  Med: -49.69 Max: -23.35
Current: -43.5
-260.49
-23.35
Net Margin % -43.17
SGEN's Net Margin % is ranked higher than
59% of the 737 Companies
in the Global Biotechnology industry.

( Industry Median: -79.00 vs. SGEN: -43.17 )
Ranked among companies with meaningful Net Margin % only.
SGEN' s Net Margin % Range Over the Past 10 Years
Min: -242.65  Med: -48.72 Max: -23.22
Current: -43.17
-242.65
-23.22
ROE % -27.61
SGEN's ROE % is ranked higher than
61% of the 853 Companies
in the Global Biotechnology industry.

( Industry Median: -36.35 vs. SGEN: -27.61 )
Ranked among companies with meaningful ROE % only.
SGEN' s ROE % Range Over the Past 10 Years
Min: -128.57  Med: -35.29 Max: -21.23
Current: -27.61
-128.57
-21.23
ROA % -21.31
SGEN's ROA % is ranked higher than
62% of the 950 Companies
in the Global Biotechnology industry.

( Industry Median: -29.87 vs. SGEN: -21.31 )
Ranked among companies with meaningful ROA % only.
SGEN' s ROA % Range Over the Past 10 Years
Min: -50.86  Med: -18.13 Max: -12
Current: -21.31
-50.86
-12
ROC (Joel Greenblatt) % -257.13
SGEN's ROC (Joel Greenblatt) % is ranked higher than
56% of the 907 Companies
in the Global Biotechnology industry.

( Industry Median: -394.49 vs. SGEN: -257.13 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
SGEN' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -903.49  Med: -405.77 Max: -178.02
Current: -257.13
-903.49
-178.02
3-Year Revenue Growth Rate 10.30
SGEN's 3-Year Revenue Growth Rate is ranked higher than
59% of the 507 Companies
in the Global Biotechnology industry.

( Industry Median: 5.10 vs. SGEN: 10.30 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
SGEN' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: 7.7  Med: 35.05 Max: 148.1
Current: 10.3
7.7
148.1
3-Year EBITDA Growth Rate 25.70
SGEN's 3-Year EBITDA Growth Rate is ranked higher than
76% of the 534 Companies
in the Global Biotechnology industry.

( Industry Median: -0.90 vs. SGEN: 25.70 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
SGEN' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -30.1  Med: 2.5 Max: 25.7
Current: 25.7
-30.1
25.7
3-Year EPS without NRI Growth Rate 25.20
SGEN's 3-Year EPS without NRI Growth Rate is ranked higher than
78% of the 519 Companies
in the Global Biotechnology industry.

( Industry Median: -2.90 vs. SGEN: 25.20 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
SGEN' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -34  Med: -1.3 Max: 27.9
Current: 25.2
-34
27.9
GuruFocus has detected 6 Warning Signs with Seattle Genetics Inc $SGEN.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» SGEN's 30-Y Financials

Financials (Next Earnings Date: 2017-07-27 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q2 2016

SGEN Guru Trades in Q2 2016

George Soros 14,700 sh (New)
Joel Greenblatt 30,082 sh (New)
PRIMECAP Management 13,514,712 sh (-0.55%)
Columbia Wanger 1,428,393 sh (-19.02%)
Manning & Napier Advisors, Inc 228,321 sh (-21.03%)
» More
Q3 2016

SGEN Guru Trades in Q3 2016

Paul Tudor Jones 8,729 sh (New)
Manning & Napier Advisors, Inc 257,580 sh (+12.81%)
PRIMECAP Management 13,420,237 sh (-0.70%)
Columbia Wanger 682,974 sh (-52.19%)
George Soros 4,347 sh (-70.43%)
Joel Greenblatt 8,242 sh (-72.60%)
» More
Q4 2016

SGEN Guru Trades in Q4 2016

Ray Dalio 163,107 sh (New)
Jim Simons 253,313 sh (New)
Joel Greenblatt 12,900 sh (+56.52%)
Columbia Wanger 760,744 sh (+11.39%)
George Soros Sold Out
Paul Tudor Jones Sold Out
PRIMECAP Management 13,230,162 sh (-1.42%)
Manning & Napier Advisors, Inc 140,670 sh (-45.39%)
» More
Q1 2017

SGEN Guru Trades in Q1 2017

Paul Tudor Jones 4,733 sh (New)
Steven Cohen 469,625 sh (New)
Joel Greenblatt 86,842 sh (+573.19%)
Ray Dalio Sold Out
Jim Simons Sold Out
PRIMECAP Management 13,182,312 sh (-0.36%)
Columbia Wanger 592,582 sh (-22.10%)
Manning & Napier Advisors, Inc 100,385 sh (-28.64%)
» More
» Details

Insider Trades

Latest Guru Trades with SGEN

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325414    SIC: 2836
Compare:NAS:JAZZ, NAS:ALKS, NAS:TSRO, NAS:ALNY, OTCPK:GMXAY, OTCPK:NVZMF, NAS:BIVV, NAS:EXEL, NAS:UTHR, NAS:IONS, NAS:NBIX, NAS:GLPG, NAS:TECH, NAS:KITE, NAS:BMRN, NAS:ACAD, NAS:BLUE, OTCPK:BTGGF, NAS:CBPO, OTCPK:UCBJY » details
Traded in other countries:SGT.Germany,
Headquarter Location:USA
Seattle Genetics Inc is a biotechnology company. It develops & commercializes monoclonal antibody-based therapies for treating cancer. Its products ADCETRIS is used for treating relapsed Hodgkin lymphoma & relapsed systemic anaplastic large cell lymphoma.

Seattle Genetics is a development-stage biotech focused on the development of monoclonal antibody-based therapies. The firm's lead product, Adcetris, has received approval for relapsed/refractory Hodgkin's lymphoma and anaplastic large-cell lymphoma, and the company has several other early-stage programs in trials. Seattle Genetics also licenses its antibody-drug conjugate technology to a number of leading biotechnology and pharmaceutical companies.

Top Ranked Articles about Seattle Genetics Inc

INVESTOR ALERT: Levi & Korsinsky, LLP Reminds Shareholders of Seattle Genetics Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of March 13, 2017 – SGEN

NEW YORK, March 08, 2017 (GLOBE NEWSWIRE) -- The following statement is being issued by Levi & Korsinsky, LLP:
To: All persons or entities who purchased or otherwise acquired securities of Seattle Genetics Inc. (“Seattle Genetics”) (NASDAQ:SGEN) between October 27, 2016 and December 23, 2016.      You are hereby notified that a securities class action lawsuit has been commenced in the United States District Court for the Western District of Washington. If you purchased or otherwise acquired Seattle Genetics securities between October 27, 2016 and December 23, 2016, your rights may be affected by this action. To get more information go to: http://www.zlk.com/pslra/seattle-genetics-inc or contact Joseph E. Levi, Esq. either via email at [email protected] or by telephone at (212) 363-7500, toll-free: (877) 363-5972. There is no cost or obligation to you. The complaint alleges that throughout the class period, Seattle Genetics made false and/or misleading statements and/or failed to disclose that: (a) its product in development, vadastuximab talirine, presents a significant risk of fatal hepatoxicity; (b) as such, Seattle Genetics had overstated the viability of vadastuximab talirine as a treatment for acute myeloid leukemia; and (c) as a result, the Company’s statements were materially false and misleading at all relevant times. On December 27, 2016, Seattle Genetics issued a press release announcing that the U.S. Food and Drug Administration had placed a clinical hold or partial clinical hold on several early stage trials of vadastuximab talirine. If you suffered a loss in Seattle Genetics you have until March 13, 2017 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff. Levi & Korsinsky is a national firm with offices in New York, New Jersey, California, Connecticut, and Washington D.C. The firm’s attorneys have extensive expertise and experience representing investors in securities litigation involving financial fraud, and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT:   
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
30 Broad Street - 24th Floor
New York, NY 10004           
Tel: (212) 363-7500
Toll Free:  (877) 363-5972
Fax: (212) 363-7171
www.zlk.com

Read more...
DEADLINE ALERT: Brower Piven Reminds Investors Of The March 13, 2017 Deadline In Class Action Lawsuit And Encourages Investors With Losses In Excess of $100,000 From Investment In Seattle Genetics Inc. (SGEN) To Contact The Firm

STEVENSON, Md., March 05, 2017 (GLOBE NEWSWIRE) -- The securities litigation law firm of Brower Piven, A Professional Corporation, announces that a class action lawsuit has been commenced in the United States District Court for the Western District of Washington on behalf of purchasers of Seattle Genetics Inc. (NASDAQ:SGEN) (“Seattle Genetics” or the “Company”) securities during the period between October 27, 2016 and December 23, 2016, inclusive (the “Class Period”). Investors who wish to become proactively involved in the litigation have until March 13, 2017 to seek appointment as lead plaintiff.
If you wish to choose counsel to represent you and the Class, you must apply to be appointed lead plaintiff and be selected by the Court. The lead plaintiff will direct the litigation and participate in important decisions including whether to accept a settlement for the Class in the action. The lead plaintiff will be selected from among applicants claiming the largest loss from investment in Seattle Genetics securities during the Class Period. Members of the Class will be represented by the lead plaintiff and counsel chosen by the lead plaintiff. No class has yet been certified in the above action. The complaint accuses the defendants of violations of the Securities Exchange Act of 1934 by virtue of the defendants’ failure to disclose during the Class Period that Seattle Genetics’ vadastuximab talirine presents a significant risk of fatal hepatotoxicity and that the Company had overstated the viability of vadastuximab talirine as a treatment for acute myeloid leukemia (“AML”). According to the complaint, following a December 27, 2016 press release announcing that the U.S. Food and Drug Administration had placed a clinical hold or partial clinical hold on several early stage trials of vadastuximab talirine to evaluate the potential risk of hepatotoxicity, the value of Seattle Genetics shares declined significantly. If you have suffered a loss in excess of $100,000 from investment in Seattle Genetics securities purchased on or after October 27, 2016 and held through the revelation of negative information during and/or at the end of the Class Period and would like to learn more about this lawsuit and your ability to participate as a lead plaintiff, without cost or obligation to you, please visit our website at http://www.browerpiven.com/currentsecuritiescases.html. You may also request more information by contacting Brower Piven either by email at [email protected] or by telephone at (410) 415-6616. Brower Piven also encourages anyone with information regarding the Company’s conduct during the period in question to contact the firm, including whistleblowers, former employees, shareholders and others. Attorneys at Brower Piven have extensive experience in litigating securities and other class action cases and have been advocating for the rights of shareholders since the 1980s. If you choose to retain counsel, you may retain Brower Piven without financial obligation or cost to you, or you may retain other counsel of your choice. You need take no action at this time to be a member of the class.
CONTACT: Charles J. Piven
Brower Piven, A Professional Corporation
1925 Old Valley Road
Stevenson, Maryland 21153
Telephone: 410-415-6616
[email protected]

Read more...
IMPORTANT SEATTLE GENETICS INC. INVESTOR REMINDER: Wolf Haldenstein Adler Freeman & Herz LLP reminds investors that a securities class action lawsuit has been filed in the Western District of Washington against Seattle Genetics Inc.

Rapidly Approaching Lead Plaintiff Deadline is March 13, 2017

NEW YORK, Feb. 28, 2017 (GLOBE NEWSWIRE) -- Wolf Haldenstein Adler Freeman & Herz LLP announces that a class action lawsuit has been filed against Seattle Genetics Inc. (“Seattle Genetics” or the “Company”) (NASDAQ:SGEN) and certain of its officers.  The class action, filed in United States District Court for the Western District of Washington is on behalf of a class consisting of all persons or entities who purchased or otherwise acquired Seattle Genetics securities between October 27, 2016 and December 23, 2016, inclusive (the “Class Period”).
Investors who have incurred losses in shares of Seattle Genetics Inc. are urged to contact the firm immediately at [email protected] or (800) 575-0735 or (212) 545-4774. You may obtain additional information concerning the action on our website, www.whafh.com. If you have purchased shares of Seattle Genetics Inc. within the class period and would like to assist with the litigation process, you may, no later than March 13, 2017, request that the Court appoint you lead plaintiff of the proposed class. Seattle Genetics develops and commercializes targeted therapies for the treatment of cancer worldwide.  Among the Company’s products in development is SGN-CD33A (vadastuximab talirine).  Throughout the Class Period,  vadastuximab talirine was  in  clinical  trials for  various  applications,  including,  in relevant part: (i) a Phase 1/2  trial in patients with acute myeloid leukemia (AML) as a pre-conditioning regimen prior to an allogenic stem cell transplant and as a maintenance therapy following transplant; (ii) a Phase 1 trial evaluating vadastuximab talirine monotherapy, including a subset of older  AML patients in combination with hypomethylating agents; and (iii) a Phase 1 trial evaluating vadastuximab talirine combination treatment with 7 3 chemotherapy in newly diagnosed younger AML patients. The filed Complaint  alleges  that throughout the Class  Period, Defendants  made materially false and/or misleading statements,  as well as failed to  disclose  material  adverse  facts  about the  Company’s  business, operations, and prospects.  Specifically, Defendants made  false and/or misleading  statements and/or  failed  to  disclose  that: (i) vadastuximab  talirine presents  a significant risk of fatal hepatotoxicity;  (ii) as such, Seattle Genetics had overstated the viability of vadastuximab talirine as an  AML treatment;  and (iii) as a result of the foregoing, Seattle Genetics’ public statements  were materially false and misleading at all relevant times.  On December 27,  2016, Seattle  Genetics issued a  press release  and filed  a Form  8-K with the  Securities and Exchange Commission (SEC) announcing that  the Food  and Drug Administration had (FDA) placed a clinical  hold or partial  clinical hold  on several  early  stage  trials  of  the  Company’s  experimental  cancer  drug,  vadastuximab talirine,  to evaluate the potential risk of hepatotoxicity. On this news, Seattle Genetics’ share price fell $9.50, or 15.36 %, to close at $52.36 on December 27, 2016. Wolf Haldenstein has extensive experience in the prosecution of securities class actions and derivative litigation in state and federal trial and appellate courts across the country.  The firm has attorneys in various practice areas; and offices in New York, Chicago and San Diego.  The reputation and expertise of this firm in shareholder and other class litigation has been repeatedly recognized by the courts, which have appointed it to major positions in complex securities multi-district and consolidated litigation. If you wish to discuss this action or have any questions regarding your rights and interests in this case, please immediately contact Wolf Haldenstein by telephone at (800) 575-0735, via e-mail at [email protected], or visit our website at www.whafh.com. ## Follow the firm and learn about newly filed cases on Twitter and Facebook. ## Attorney Advertising. Prior results do not guarantee or predict a similar outcome.
Contact:

Wolf Haldenstein Adler Freeman & Herz LLP
Patrick Donovan, Esq.
Gregory Stone, Director of Case and Financial Analysis
Email: [email protected], [email protected] or [email protected]
Tel: (800) 575-0735 or (212) 545-4774

Read more...

Ratios

vs
industry
vs
history
PB Ratio 15.43
SGEN's PB Ratio is ranked lower than
89% of the 844 Companies
in the Global Biotechnology industry.

( Industry Median: 3.75 vs. SGEN: 15.43 )
Ranked among companies with meaningful PB Ratio only.
SGEN' s PB Ratio Range Over the Past 10 Years
Min: 1.88  Med: 9.54 Max: 35.99
Current: 15.43
1.88
35.99
PS Ratio 22.22
SGEN's PS Ratio is ranked lower than
64% of the 685 Companies
in the Global Biotechnology industry.

( Industry Median: 12.47 vs. SGEN: 22.22 )
Ranked among companies with meaningful PS Ratio only.
SGEN' s PS Ratio Range Over the Past 10 Years
Min: 10.06  Med: 19.12 Max: 45.33
Current: 22.22
10.06
45.33
EV-to-EBIT -48.71
SGEN's EV-to-EBIT is ranked lower than
99.99% of the 423 Companies
in the Global Biotechnology industry.

( Industry Median: 22.87 vs. SGEN: -48.71 )
Ranked among companies with meaningful EV-to-EBIT only.
SGEN' s EV-to-EBIT Range Over the Past 10 Years
Min: -102.6  Med: -21.4 Max: -2.8
Current: -48.71
-102.6
-2.8
EV-to-EBITDA -54.35
SGEN's EV-to-EBITDA is ranked lower than
99.99% of the 466 Companies
in the Global Biotechnology industry.

( Industry Median: 17.12 vs. SGEN: -54.35 )
Ranked among companies with meaningful EV-to-EBITDA only.
SGEN' s EV-to-EBITDA Range Over the Past 10 Years
Min: -120.2  Med: -23 Max: -3.1
Current: -54.35
-120.2
-3.1
Current Ratio 5.09
SGEN's Current Ratio is ranked higher than
57% of the 921 Companies
in the Global Biotechnology industry.

( Industry Median: 4.05 vs. SGEN: 5.09 )
Ranked among companies with meaningful Current Ratio only.
SGEN' s Current Ratio Range Over the Past 10 Years
Min: 2.65  Med: 5.23 Max: 30.03
Current: 5.09
2.65
30.03
Quick Ratio 4.62
SGEN's Quick Ratio is ranked higher than
55% of the 920 Companies
in the Global Biotechnology industry.

( Industry Median: 3.77 vs. SGEN: 4.62 )
Ranked among companies with meaningful Quick Ratio only.
SGEN' s Quick Ratio Range Over the Past 10 Years
Min: 2.29  Med: 5.05 Max: 30.03
Current: 4.62
2.29
30.03
Days Inventory 543.53
SGEN's Days Inventory is ranked lower than
96% of the 436 Companies
in the Global Biotechnology industry.

( Industry Median: 126.28 vs. SGEN: 543.53 )
Ranked among companies with meaningful Days Inventory only.
SGEN' s Days Inventory Range Over the Past 10 Years
Min: 442.93  Med: 547.11 Max: 639.76
Current: 543.53
442.93
639.76
Days Sales Outstanding 64.63
SGEN's Days Sales Outstanding is ranked higher than
55% of the 596 Companies
in the Global Biotechnology industry.

( Industry Median: 61.11 vs. SGEN: 64.63 )
Ranked among companies with meaningful Days Sales Outstanding only.
SGEN' s Days Sales Outstanding Range Over the Past 10 Years
Min: 40  Med: 61.69 Max: 562.77
Current: 64.63
40
562.77
Days Payable 237.27
SGEN's Days Payable is ranked higher than
86% of the 409 Companies
in the Global Biotechnology industry.

( Industry Median: 58.37 vs. SGEN: 237.27 )
Ranked among companies with meaningful Days Payable only.
SGEN' s Days Payable Range Over the Past 10 Years
Min: 202.64  Med: 240.81 Max: 1833.79
Current: 237.27
202.64
1833.79

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -5.10
SGEN's 3-Year Average Share Buyback Ratio is ranked higher than
73% of the 571 Companies
in the Global Biotechnology industry.

( Industry Median: -11.10 vs. SGEN: -5.10 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
SGEN' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -113.5  Med: -12.05 Max: -2.2
Current: -5.1
-113.5
-2.2

Valuation & Return

vs
industry
vs
history
Price-to-Net-Cash 28.68
SGEN's Price-to-Net-Cash is ranked lower than
83% of the 514 Companies
in the Global Biotechnology industry.

( Industry Median: 6.54 vs. SGEN: 28.68 )
Ranked among companies with meaningful Price-to-Net-Cash only.
SGEN' s Price-to-Net-Cash Range Over the Past 10 Years
Min: 2.12  Med: 12.56 Max: 284.71
Current: 28.68
2.12
284.71
Price-to-Net-Current-Asset-Value 19.63
SGEN's Price-to-Net-Current-Asset-Value is ranked lower than
81% of the 630 Companies
in the Global Biotechnology industry.

( Industry Median: 6.07 vs. SGEN: 19.63 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
SGEN' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 2.09  Med: 10.01 Max: 447
Current: 19.63
2.09
447
Price-to-Tangible-Book 15.46
SGEN's Price-to-Tangible-Book is ranked lower than
86% of the 769 Companies
in the Global Biotechnology industry.

( Industry Median: 4.58 vs. SGEN: 15.46 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
SGEN' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 1.78  Med: 7.18 Max: 33.75
Current: 15.46
1.78
33.75
Price-to-Median-PS-Value 1.16
SGEN's Price-to-Median-PS-Value is ranked lower than
59% of the 584 Companies
in the Global Biotechnology industry.

( Industry Median: 0.98 vs. SGEN: 1.16 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
SGEN' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.54  Med: 1.13 Max: 30
Current: 1.16
0.54
30
Earnings Yield (Greenblatt) % -2.01
SGEN's Earnings Yield (Greenblatt) % is ranked higher than
63% of the 1272 Companies
in the Global Biotechnology industry.

( Industry Median: -6.37 vs. SGEN: -2.01 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
SGEN' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -4.02  Med: 0 Max: 0
Current: -2.01
-4.02
0

More Statistics

Revenue (TTM) (Mil) $416.1
EPS (TTM) $ -1.27
Beta2.52
Short Percentage of Float11.75%
52-Week Range $35.93 - 75.36
Shares Outstanding (Mil)142.72

Analyst Estimate

Dec17 Dec18 Dec19
Revenue (Mil $) 438 592 870
EPS ($) -1.75 -0.98 0.40
EPS without NRI ($) -1.75 -0.98 0.40
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)
» More Articles for SGEN

Headlines

Articles On GuruFocus.com
INVESTOR ALERT: Levi & Korsinsky, LLP Reminds Shareholders of Seattle Genetics Inc. of a Class Actio Mar 08 2017 
DEADLINE ALERT: Brower Piven Reminds Investors Of The March 13, 2017 Deadline In Class Action Lawsui Mar 05 2017 
IMPORTANT SEATTLE GENETICS INC. INVESTOR REMINDER: Wolf Haldenstein Adler Freeman & Herz LLP remi Feb 28 2017 
7 Stocks That Are Beating the Market Feb 21 2017 
Insiders Buy Herbalife, Sell MasterCard Nov 05 2016 
Insiders Roundup: Theravance Biopharma, Western Gas, Upland Software Mar 18 2016 
Top Insider Trades of the Past Week Feb 19 2016 
Insiders Are Buying Barnes & Noble Sep 18 2015 
Vanguard Health Care Fund Buys Two New Stakes in Second Quarter Aug 06 2015 
Insiders keep on buying Macerich Co and Seattle Genetics May 22 2015 

More From Other Websites
Seattle Genetics, Inc. breached its 50 day moving average in a Bullish Manner : SGEN-US : May 19,... May 19 2017
Seattle Genetics to Present at Bank of America Merrill Lynch 2017 Healthcare Conference May 09 2017
The Head-Scratching Reason Immunomedics Rose by as Much as 12% May 08 2017
Immunomedics Breaks Out, But Will It Last? May 08 2017
Did Immunomedics Rise Too Much as Seattle Genetics Deal Terminated? May 06 2017
Immunomedics, Seattle Genetics Scrap License Deal May 05 2017
Why Immunomedics, Inc. Rocketed Today May 05 2017
Biotech Movers: Immunomedics Shares Jump After License Pact with Seattle Genetics Is Terminated May 05 2017
Seattle Genetics Terminates License Agreement with Immunomedics for Sacituzumab Govitecan (IMMU-132) May 05 2017
ETFs with exposure to Seattle Genetics, Inc. : May 4, 2017 May 04 2017
Seattle Genetics, Inc. :SGEN-US: Earnings Analysis: Q1, 2017 By the Numbers : May 3, 2017 May 03 2017
Seattle Genetics, Inc. breached its 50 day moving average in a Bearish Manner : SGEN-US : May 3,... May 03 2017
Seattle Genetics, Inc. Earnings: Solid Quarter, but Investors Wait May 01 2017
Edited Transcript of SGEN earnings conference call or presentation 27-Apr-17 8:30pm GMT Apr 30 2017
Seattle Genetics (SGEN) Q1 Loss Widens, Sales Top Estimates Apr 28 2017
Seattle Genetics reports 1Q loss Apr 27 2017
Seattle Genetics Reports First Quarter 2017 Financial Results Apr 27 2017
Investor Network: Seattle Genetics, Inc. to Host Earnings Call Apr 27 2017
Why Immunomedics, Inc. Got Hammered Today Apr 21 2017
Seattle Genetics, Inc. breached its 50 day moving average in a Bullish Manner : SGEN-US : April 14,... Apr 14 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)